Reports Q4 revenue $647M, consensus $638.81M. “The Exact Sciences team advanced our mission to help eradicate cancer by testing a record number of patients with Cologuard and Oncotype DX in the fourth quarter, leading to strong financial results,” said Kevin Conroy, Chairman and CEO of Exact Sciences. “Over the past decade, we have built a world-class team and unrivaled platform that is fueling predictable, profitable growth and powering the next wave of innovative cancer diagnostics to make a profound difference in the fight against cancer.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EXAS:
- LLY, CVS, EXAS: Which Strong-Buy-Rated Healthcare Stock Is the Better Buy?
- Is EXAS a Buy, Before Earnings?
- BIIB, ZTS, EXAS: Which “Strong Buy” Healthcare Stock is Best?
- Exact Sciences (NASDAQ:EXAS) Announces Strong Preliminary Q4 Results and CFO Transition
- Exact Sciences says Jeff Elliott stepping down as executive VP, CFO
